Repros Therapeutics (RPRX) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results
March 14, 2016 9:15 AM EDTTHE WOODLANDS, Texas, March 14, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced financial results for the fourth quarter and year ended December 31, 2015.
Financial Results
Net loss for the three month period ended December 31, 2015, was ($6.3) million or ($0.26) per share as compared to a net loss of ($7.4) million or ($0.31) per share for the same period in 2014. The net loss for the year ended December 31, 2015, was ($29.2) million or ($1.20) per share as compared to a net loss of ($32.5) million or ($1.39) per share for 2014. The decreases... More
